- Home
- FSBC vs REPL Comparison
FSBC vs REPL Comparison
Compare FSBC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FSBC | REPL |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.1M | 692.8M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FSBC | REPL |
|---|---|---|
| Price | $37.72 | $8.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $40.75 | $11.13 |
| AVG Volume (30 Days) | 53.4K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 2.65% | N/A |
| EPS Growth | ★ 28.32 | 5.25 |
| EPS | ★ 2.90 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.27 | N/A |
| Revenue Next Year | $12.35 | N/A |
| P/E Ratio | $13.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.22 | $2.68 |
| 52 Week High | $42.26 | $13.24 |
Technical Indicators
Market Signals| Indicator | FSBC | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 60.97 |
| Support Level | $36.20 | $8.24 |
| Resistance Level | $38.25 | $8.82 |
| Average True Range (ATR) | 1.51 | 0.58 |
| MACD | -0.38 | 0.05 |
| Stochastic Oscillator | 27.82 | 97.54 |
Price Performance
Historical ComparisonAbout FSBC Five Star Bancorp
Five Star Bancorp is a bank holding company through its subsidiary it operates in California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment; Banking.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.